Cargando…

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Platinum-based chemotherapy is the standard first-line treatment for non-oncogene-addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonanno, Laura, Costa, Carlota, Majem, Margarita, Sanchez, Jose Javier, Gimenez-Capitan, Ana, Rodriguez, Ignacio, Vergenegre, Alain, Massuti, Bartomeu, Favaretto, Adolfo, Rugge, Massimo, Pallares, Cinta, Taron, Miquel, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858546/
https://www.ncbi.nlm.nih.gov/pubmed/24197907
_version_ 1782295288026759168
author Bonanno, Laura
Costa, Carlota
Majem, Margarita
Sanchez, Jose Javier
Gimenez-Capitan, Ana
Rodriguez, Ignacio
Vergenegre, Alain
Massuti, Bartomeu
Favaretto, Adolfo
Rugge, Massimo
Pallares, Cinta
Taron, Miquel
Rosell, Rafael
author_facet Bonanno, Laura
Costa, Carlota
Majem, Margarita
Sanchez, Jose Javier
Gimenez-Capitan, Ana
Rodriguez, Ignacio
Vergenegre, Alain
Massuti, Bartomeu
Favaretto, Adolfo
Rugge, Massimo
Pallares, Cinta
Taron, Miquel
Rosell, Rafael
author_sort Bonanno, Laura
collection PubMed
description Platinum-based chemotherapy is the standard first-line treatment for non-oncogene-addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P <0.0001) and overall survival was 8.2 months (P=0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy.
format Online
Article
Text
id pubmed-3858546
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-38585462013-12-11 The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy Bonanno, Laura Costa, Carlota Majem, Margarita Sanchez, Jose Javier Gimenez-Capitan, Ana Rodriguez, Ignacio Vergenegre, Alain Massuti, Bartomeu Favaretto, Adolfo Rugge, Massimo Pallares, Cinta Taron, Miquel Rosell, Rafael Oncotarget Research Paper Platinum-based chemotherapy is the standard first-line treatment for non-oncogene-addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P <0.0001) and overall survival was 8.2 months (P=0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy. Impact Journals LLC 2013-07-31 /pmc/articles/PMC3858546/ /pubmed/24197907 Text en Copyright: © 2013 Bonanno et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Research Paper
Bonanno, Laura
Costa, Carlota
Majem, Margarita
Sanchez, Jose Javier
Gimenez-Capitan, Ana
Rodriguez, Ignacio
Vergenegre, Alain
Massuti, Bartomeu
Favaretto, Adolfo
Rugge, Massimo
Pallares, Cinta
Taron, Miquel
Rosell, Rafael
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
title The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
title_full The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
title_fullStr The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
title_full_unstemmed The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
title_short The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
title_sort predictive value of 53bp1 and brca1 mrna expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858546/
https://www.ncbi.nlm.nih.gov/pubmed/24197907
work_keys_str_mv AT bonannolaura thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT costacarlota thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT majemmargarita thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT sanchezjosejavier thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT gimenezcapitanana thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT rodriguezignacio thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT vergenegrealain thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT massutibartomeu thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT favarettoadolfo thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT ruggemassimo thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT pallarescinta thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT taronmiquel thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT rosellrafael thepredictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT bonannolaura predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT costacarlota predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT majemmargarita predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT sanchezjosejavier predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT gimenezcapitanana predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT rodriguezignacio predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT vergenegrealain predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT massutibartomeu predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT favarettoadolfo predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT ruggemassimo predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT pallarescinta predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT taronmiquel predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy
AT rosellrafael predictivevalueof53bp1andbrca1mrnaexpressioninadvancednonsmallcelllungcancerpatientstreatedwithfirstlineplatinumbasedchemotherapy